Roberta Duncan, Seqirus mRNA program head (Seqirus)

CSL's Se­qirus, spurred on by Covid-19 mR­NA vac­cines, props up new unit for 'self-am­pli­fy­ing' shot tech

The Covid-19 pan­dem­ic has of­fered proof of con­cept for the promise of mR­NA vac­cines, and now CSL Behring’s Se­qirus unit wants to take the next step with tech­nol­o­gy it thinks will dri­ve the field even fur­ther in­to the fu­ture.

Se­qirus will carve out a new busi­ness unit built around its self-am­pli­fy­ing mR­NA vac­cine work against in­fluen­za, the com­pa­ny said Thurs­day, be­com­ing the lat­est ma­jor play­er to dive head­first in­to the field af­ter the suc­cess of the Covid-19 jabs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.